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Abstract 
The NF-κB p50 subunit is an important regulator of inflammation, with recent experimental 
evidence to support it also having a tumor suppressor role. Classically, p50 functions in 
heterodimeric form with the RelA (p65) NF-κB subunit to activate inflammatory genes. 
However, p50 also forms homodimers which actively repress NF-κB-dependent inflammatory 
gene expression and exert an important brake on the inflammatory process. This repressive 
activity of p50:p50 is thought to be in part mediated by an interaction with the epigenetic 
repressor protein Histone Deacetylase 1 (HDAC1). However, neither the interaction of p50 with 
HDAC1 nor the requirement of HDAC1 for the repressive activities of p50 have been well 
defined. Here we employed in silico prediction with in vitro assays to map sites of interaction of 
HDAC1 on the p50 protein. Directed mutagenesis of one such region resulted in almost complete 
loss of HDAC1 binding to p50. Transfected mutant p50 protein lacking the putative HDAC1 
docking motif resulted in enhanced cytokine and chemokine expression when compared with 
cells expressing a transfected wild type p50. In addition, expression of this mutant p50 was 
associated with enhanced chemoattraction of neutrophils and acetylation of known inflammatory 
genes demonstrating the likely importance of the p50:HDAC1 interaction for controlling 
inflammation. These new insights provide an advance on current knowledge of the mechanisms 
by which NF-κB-dependent gene transcription are regulated and highlight the potential for 
manipulation of p50:HDAC1 interactions to bring about experimental modulation of chronic 
inflammation and pathologies associated with dysregulated neutrophil accumulation and 
activation. 
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1. Introduction 
NF-κB is a family of five transcription factors (RelA (p65), RelB, c-Rel, p100/p52 p105/p50), 
that combine to control expression of hundreds of genes that impact on the regulation of cell 
proliferation and survival, differentiation, inflammation, metabolism, tissue repair and 
regeneration, fibrosis and cancer [1]. The most well-known and functionally characterized form 
of NF-κB is the so-called canonical RelA:p50 heterodimer that is activated in response to a 
variety of extracellular inflammatory stimuli (e.g. TNF, IL-1 and LPS).  RelA:p50 is required for 
mounting inflammatory responses through RelA-mediated transcriptional activation of key 
cytokine and chemokine genes. Given the potential for inflammation to cause tissue damage, the 
activities of RelA are tightly regulated by a variety of inhibitory checkpoints and negative 
feedback mechanisms [2]. A major focus for our laboratory has been the functions of the p50 
NF-κB subunit expressed from the NFKB1 gene and in particular its distinct role when operating 
without RelA as a dimer partner [3]. Expression of p50 is found in most cell types under resting 
conditions, however the subunit can be induced to higher levels of expression in response to 
inflammatory stimuli [4]. Although p50 is generated directly from NFKB1 transcripts [5], a 
predominant source in inflammatory states is via processing of its p105 precursor. This 
processing involves signal-induced, ubiquitin-dependent limited proteolysis regulated by the 
KPC1 ubiquitin E3 ligase [6]. An important structural feature of p50 is its lack of the 
transactivation domain typically found in the Rel proteins, as such it relies upon its Rel 
dimerization partners (RelA, c-Rel and RelB) to induce gene expression. Importantly, p50 can 
also form homodimers, their assembly being under distinct post-translational control with 
evidence for the requirement of specific serine residues (e.g. Ser-65, Ser-337 and Ser-340) which 
appear to be non-essential for heterodimerisation [3,7]. These observations raise the potential for 
selective modulation of NF-κB activities that are under the control of p50:p50 dimers.  
In striking contrast to embryonic lethality found in rela-/- mice, the absence of p50 in nfkb1-/- 
mice results in loss of immune tolerance, heightened inflammatory responses to tissue damage 
and spontaneous inflammatory-driven ageing, these phenotypes collectively indicating that p50 
exerts important anti-inflammatory control in tissues [8]. We recently confirmed by a genetic 
approach that these anti-inflammatory effects are a consequence of activities of the p50:p50 
homodimer. Mice genetically engineered to be selectively incapable of the assembly of 
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homodimers phenocopied many of the pro-inflammatory features of nfkb1-/- mice [3]. The 
precise mechanism by which homodimers suppress inflammation remains poorly defined, but 
may involve direct competition with Rel-containing dimers for occupancy of κB DNA binding 
motifs or a more active process in which recruitment of histone deacetylases promotes local 
chromatin remodeling into a repressed state [9]. In both cases, the interaction of the homodimer 
with co-repressors is an important regulatory feature. Bcl3 is an IκB-like protein that has been 
reported to directly physically combine with p50:p50 dimers to prevent ubiquitin-mediated 
degradation and thereby enhances the stability of homodimers bound at κB DNA binding motifs 
[10]. HDAC1 is a class I nuclear histone deacetylase that is also proposed to physically complex 
with p50 homodimers and to mediate repressive histone deacetylation of local chromatin at NF-
κB-regulated genes. It is additionally suggested that CCAAT enhancer-binding proteins (C/EBP) 
may selectively remove HDAC1 from homodimers resulting in release of a subset of NF-κB 
target genes from transcriptional repression [11]. However, the precise nature of the interaction 
of the HDACs with p50 is poorly defined and the degree to which HDAC:p50 interactions 
contribute to the control of transcription is unclear.  
Here, we define a specific site of interaction of HDAC1 on the p50 protein and report that 
mutation of this HDAC1 binding motif results in modulation of histone acetylation at a subset of 
NF-κB target genes and is associated with elevated chemokine expression and enhanced 
neutrophil chemotaxis. These discoveries significantly advance our understanding of a 
transcriptional repression mechanism that acts as a physiologically important constraint on NF-
κB-dependent inflammation. 
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2. Materials and Methods 
2.1 Cell Culture 
Cos-7, U2OS, HELA and nfkb1-/- Murine Embryonic Fibroblasts (MEFs) were maintained in 
DMEM (GIBCO) supplemented with 100 U/ml penicillin, 100μg/ml streptomycin, 2mM 
L-glutamine and 10% fetal bovine serum at 37°C at an atmosphere of 5% CO2  
2.2 Generation of Mutant p50-FLAG Constructs 
Mutant constructs were all generated from a parent p50-FLAG pcDNA3.1 backbone kindly 
provided by N. D. Perkins (Newcastle University). Mutations were generated using a Q5 
Site-Directed Mutagenesis Kit (E0554S, New England Biolabs). Briefly, template p50-FLAG 
pcDNA3.1 was incubated 95°C followed by 3 minute cycles at the appropriate annealing 
temperate with a final incubation at 72°C for 10 minutes. This linear mutant DNA was then 
circularized using the KDL enzyme mix at room temperature for 15 minutes and products 
transformed into DH5α competent E.Coli (C2987H, New England Biolabs) and colonies selected 
by antibiotic resistance. Plasmids were then purified using an Endotoxin Free Plasmid Maxi Kit 
(12163, Qiagen). All mutants were confirmed by Sanger sequencing (GATC Bio-tech). Primers 
used in mutagenesis can be found in Table 1.  
2.3 Transfection, Co-Transfection and Luciferase Reporter Assay 
Generated mammalian expression constructs were transfected into Cos-7, U2OS, HELA and 
nfkb1-/- MEF cell lines for 48 hours (ChIP Assays), 24 hours (Nuclear localization, Luciferase 
Assay, Endogenous and FLAG Co-IP) or 18 hours (followed by TNFα treatment for 6 hours at 
10ng/ml) using Effectene Transfection reagent (301427, Qiagen) following manufacturer’s 
instructions. Briefly, cells were seeded to 40-60% confluency and DNA for transfection 
incubated in EC Buffer with Enhancer and Effectene reagent for 5 and 10 minutes respectively. 
This mixture was further diluted in DMEM and added to cells under normal culture conditions 
for the indicated time period. Following incubation cells were then harvested for Western Blot, 
Precipitation assays or Luciferase assay. Luciferase assays were performed using a Dual 
Luciferase Assay Reporter System (E1910, Promega) following manufacturer’s instructions. 
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Relative luminescence was normalized to co-transfected Renilla luciferase, control luciferase 
reporter as well as total protein. Transfection DNA concentrations can be found in Table 2. 
2.4 Endogenous Co-Immunoprecipitation and FLAG Immunoprecipitation Assay 
Tissue or cells were washed in PBS and lysed in Co-IP lysis buffer (50mM Tris-HCL pH 7.4, 
150mM NaCl, 1mM EDTA and 1% Triton-X) with fresh protease inhibitors (118735801 Roche). 
25μg of lysate was kept as input and 500μg of lysate was incubated with 2μg of anti p105/p50 
(D7H5M CST), nuclear localization specific anti p50/p105 (sc-114x Santa Cruz), anti-p65 (sc 
372 Santa Cruz), anti IκBα (L35AS CST), normal IgG (ab46540-1 Abcam) or anti-FLAG beads 
(A2220 Sigma) for 1 hour at 4°C diluted to a total volume of 500μl in Wash Buffer (50mM Tris-
HCL pH 7.4 and 150mM NaCl). Apart from samples with FLAG beads, a 1:1 mix of Protein A 
and Protein G agarose beads (P6649 and P3296 Sigma) were then added to samples and 
incubated a further hour at 4°C. All samples were then washed in Wash Buffer and bound 
complexes eluted by boiling with 1X SDS-Loading Dye at 95°C or by incubation with Wash 
Buffer containing excess FLAG peptide in the case of FLAG IPs. Samples along with inputs 
were then assessed by Western Blot. 
2.5 Western Blot 
Total cells lysates or immunoprecipitated samples were quantified by DC protein assay (BioRad) 
and equal amounts fractionated by 8% SDS-PAGE, transferred to nitrocellulose membrane and 
blocked in Tris-buffered saline and Tween 20 (0.1%) containing 5% milk protein before 
overnight incubation (1 hour for HRP conjugates) with primary antibodies to (1:1000) p65 
(sc372 Santa Cruz), (1:2000) GAPDH (ab22555 Abcam), (1:1000) nfkb1-HRP conjugate 
(ab195854 Abcam) or (1:1000) HDAC1-HRP conjugate (ab193096 Abcam). Next, membranes 
were washed in TBS-T and further incubated with (1:1000) HRP-conjugated mouse anti-rabbit 
IgG (7074S CST). After a final wash antigens were detected by chemiluminesence (Amersham 
Biosciences). 
2.6 Nuclear and Cytoplasmic Extracts 
8x105 U2OS, 6x105 nfkb1-/- or 6x105 WT MEF cells were transfected with either 200ng/ml or 
50ng/ml WT, p50Mu or vehicle. Cells were treated with 10ng/ml TNFɑ for 6 hours or media alone 
and subsequently washed with PBS and cell pellets lysed in cytoplasmic lysis buffer (50mM 
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Tris-HCL pH 7.4, 50mM NaCl, 1mM EDTA, protease inhibitors and 0.1% Triton-X) and 
homogenized using a 27G needle. Supernatant was kept as cytoplasmic extract and pelleted 
nuclei were washed in cytoplasmic lysis buffer and resuspended in RIPA lysis buffer. Samples 
were then analyzed by western blot. 
2.7 Immunofluorescence Microscopy 
U2OS cells were seeded at 40-50% confluency in 4 well chamber slides and transfected with 
250ng/ml of either WT p50-FLAG, p50Mu-FLAG or vehicle only and incubated for 24 hours. 
Cells were then washed with PBS and fixed in 4% formaldehyde followed by permeabilization 
with 0.1% Triton-X and blocked for 1 hour in 5% Bovine Serum Albumin(BSA). Cells were 
then incubated over night at 4° with anti-FLAG-FITC antibody (F4049, Sigma) in 5% BSA. 
Cells were then washed in PBS and mounted with ProLong Gold Antifade Mountant with DAPI 
(P36935, Thermo-Fisher) and imaged on a Nikon upright Confocal Microscope at x200. 
2.8 Enzyme Linked Immunosorbent Assay 
Enzyme Linked Immunosorbent Assay Mouse IL-6 DuoSet (DY406, R&D Systems) was used to 
quantify total mouse IL-6 in supernatant of nfkb1-/- MEFs transfected with Vehicle, WT or p50Mu 
for 18 hours followed by treatment with or without TNFα (10ng/ml) for 6 hours. This sandwich 
ELISA was performed as per manufacture instruction. 
2.9 Chromatin Immunoprecipitation (ChIP) 
Briefly, nfkb1-/- MEFs transfected for 48 hours with 200ng/ml WT p50, p50Mu or vehicle only 
were cross-linked by addition of formalin at 1% final concentration for 5 minutes at RT, then 
quenched with glycine buffer at final concentration of 125 mM. The cells were rinsed in cold 
PBS, and harvested into PBS with protease inhibitors and centrifuged for 5 min, 4°C, 1,000 x g. 
The pellet was resuspended in ChIP lysis buffer (1% SDS, 10mM EDTA, 50mM Tris-HCl 
pH8.1) and incubated for 20 min on ice. Lysate was sonicated to generate average size fragments 
of 200-700bp; cell debris was pelleted by centrifugation for 10 min, 4°C, 8,000 x g. 25 μg of 
chromatin per IP was diluted 1:10 with dilution buffer (1.1% Triton, 1.2mM EDTA, 16.7mM 
TRIS-HCl pH8.1,167mM NaCl, with protease inhibitors) and precleared by incubating with 25 
μl blocked Staph A membranes (Sigma, P7155) for 15 minutes. Pre-cleared chromatin was then 
incubated with 5 μg anti acetyl H3 (ab47915, Abcam), anti p50/p105 (ab7971, Abcam)  or 
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irrelevant IgG (ab171870, Abcam) overnight at 4°C. Immunoprecipitated chromatin was 
collected with blocked Staph A membranes, which were then sequentially washed with cold 
buffers; Low Salt Wash Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl 
pH 8.0, 150 mM NaCl), High Salt Wash Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 
mM Tris-HCl pH 8.0, 500 mM NaCl), LiCl Wash Buffer (0.25 M LiCl, 1% NP-40, 1% Sodium 
Deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8.0) and two washes in TE Buffer (10 mM 
Tris pH 8.0, 1 mM EDTA). The immunoprecipitated chromatin was eluted in 500 μl Elution 
buffer (1% SDS,100mM NaHCO3), cross-links reversed and DNA obtained by 
phenol:chloroform extraction and gel purification. The level of Cxcl1 and Cxcl2 gene promoter 
association with acetylated H3 were quantitatively measured by real-time PCR using primers 
listed Table 1. 
  
2.10 RNA Isolation and Quantitative Real Time PCR 
Total RNA was isolated from cells using an RNeasy Mini Kit (74104, Qiagen) and treated with 
DNAse. This RNA was then used as a template for the synthesis of complementary DNA using 
random primers (Promega). SYBR Green quantitative RT-PCR was performed using primers 
listed in Table 1. 
2.11 Neutrophil Isolation and Chemotaxis Assay 
Bone marrow derived neutrophils were isolated from the femur and tibia of C57BL/6 WT mice 
by flushing HBSS supplemented with 20mM HEPES and 0.5% fetal calf serum. Red blood cells 
were lysed with BD PharmLyse buffer (BD Biosciences; Ref: 555899) and cellular debris 
removed using a 40μm filter. Neutrophils were isolated by negative depletion of non-target cells 
through magnetic-labelling and column separation (Neutrophil Isolation Kit - Mouse, Miltenyi 
Biotec; Ref: 130-097-658). 5x105 isolated neutrophils were then added to 3μm inserts in 
complete DMEM which were inserted into wells containing media from nfkb1-/- MEFs 
reconstituted with WT p50, p50Mu, vehicle controls or unconditioned media only with or without 
TNFα. After 2 hours neutrophils that migrated into the lower chamber were stained with trypan 
blue and counted by hemocytometer. Chemotaxis was performed in triplicate with n=3 
conditioned media. 
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2.12 p50 Peptide and Substitution Array 
p50 peptide and alanine substitution arrays were kindly provided by the Kiely Lab and were 
generated as previously described [12]. Membranes were blocked in 5% TBS-T for one hour 
followed by incubation with anti (1:5000) 6x-His Tag Monoclonal Antibody HRP (R931-25, 
Invitrogen) for 2 hours at room temperature and developed by chemiluminescence (Amersham 
Biosciences) to assess peptide antibody cross reactivity. 6xHis tagged recombinant HDAC1 (14-
838, Millipore) at 5μg/ml in 1% milk TBS-T was then added over night at 4°C followed by TBS-
T wash and incubation again with antibody and detection as described. This procedure was also 
performed on the p50 alanine substitution array. Images are representative of two independent 
arrays. 
2.13 GRAMM-X Protein Interaction Prediction and Visualization 
p50 HDAC1 interaction predictions were performed by the GRAMM-X software for ridged body 
protein-protein interactions. Chain A and B of the available crystal structure of the p50 
homodimer (PDB ID:1NFK [13]) were used as a receptor molecule for its ligand, chain B of the 
HDAC1 crystal structure (PDB ID:4BKX [14]). Potential interacting intermolecular hydrogen 
bonds were calculated using the HBond function in UCSC Chimera with relaxed bond 
constraints of 7Å and 20% bond angle flexibility. Structural modelling and images were 
generated in UCSC Chimera [15]. 
2.14 Transfection Efficiency 
2x104 nfkb1-/- MEF’s were seeded in 4 well chamber slides and transfected with 200ng/ml 
pcDNA3 GFP and imaged after 24 hours at x100 magnification. pcDNA3 EGFP was a gift from 
Doug Golenbock (Addgene plasmid # 13031). 
2.15 Statistical Analysis 
Data are expressed as mean ± S.E.M. Microsoft Excel was used to perform unpaired Students t-
test and one way A.N.O.V.A.s and *P<0.05, **P<0.01 or ***P<0.001 was considered 
significant. 
 
10 
 
3. Results and Discussion 
3.1 p50 Interacts with HDAC1 in primary and transformed cells. 
Previous in vitro biochemical investigations in mouse leukemia cell lines demonstrated potential 
for a  p50:HDAC1 interaction [16]. However, as it has yet to be demonstrated in vivo, we 
established co-immunoprecipitation (CoIP) assays to detect p50:HDAC1 interactions from 
primary cells. As shown in Fig 1A, under resting conditions in mouse liver tissue we were able 
to CoIP HDAC1 with an anti-p50/p105 antibody indicating an interaction does occur between 
the two proteins in primary tissue. We also confirmed detection of the interaction in human Hela 
cells and demonstrated that stimulation with TNFα led to reduced CoIP of HDAC1 (Supp. 1A). 
We conclude that a p50:HDAC1 complex can be detected in primary and cell  lines and may be 
modulated in response to inflammatory stimuli, the latter in keeping with a model in which 
stimulated release of HDAC1 from p50 may serve to relieve HDAC1-mediated transcriptional 
repression at NF-κB target genes [11]. It should be noted this suggests that TNFα does not 
disrupt the p50:HDAC1 interaction directly, however, it is thought that it may allow the release 
of p65 and shifts the composition of dimers from a repressive p50:p50:HDAC1 complex to that 
of a p65:p50 heterodimer which can then recruit co-factors including histone acetyl transferases, 
to upregulate gene transcription. 
We next employed in silico modelling to determine potential sites of interaction of HDAC1 on 
the p50 protein in the context of the structure determined from its DNA-bound homodimer form. 
Using the GRAMM-X server for rigid body interactions we determined the highest scoring 
possible orientations for predicted binding of HDAC1, taking into account molecular symmetry 
and potential DNA clashes (Supp. 1B) [17]. This analysis identified two physically distinct sites 
of predicted HDAC1 interaction on p50 that are shown in Fig 1B. An important caveat of this 
analysis is that calculations were restricted by the incomplete resolved crystal structure of both 
proteins (p50 PDB: 1NFK [13], HDAC1 PDB: 4BKX [14]). However, this prediction still 
provides valuable information as it pertains to the broad regions of affinity between the two 
molecules and their suitability for direct interaction. To biochemically test this in silico data, we 
employed an array of 18 amino acid long peptides that overlap and span the full length of p50 to 
determine regions of the protein with the potential to directly bind to recombinant HDAC1. 
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Peptides shown under UV (Supp. 1C) were first probed for non-specific binding using detection 
antibody (Supp. D) before being incubated with and probed for HDAC1 binding. Four major 
regions of interaction were revealed and are identified by distinct color shading in the primary 
sequence format in Fig 1C and in a structural format in Fig 1D. Importantly, these peptide 
interactions confirmed the two predicted interaction sites on p50 determined by the in silico 
analysis. We therefore conclude that HDAC1 may complex with p50 via physical interactions at 
two distinct regions of the NF-κB subunit. One of these two sites, located at the far c-terminal 
region of p50 (shaded in yellow) particularly attracted our attention as it showed consistent 
binding with HDAC1 across multiple peptides (Fig 1C), matched the highest scoring for 
interaction in the in silico analysis and has previously been reported as a site of interaction of 
p50 with IκBα and Bcl3 [18,19]. Additionally, the other potential site (blue) highlighted residues 
with poorer accessibility which reside near the DNA binding domain of p50. 
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Figure 1. p50 Associates with HDAC1 in vivo 
A. Western Blot analysis of an endogenous co-immunoprecipitation showing HDAC1 precipitates in 
complex with p50 in untreated three-month-old WT whole liver extracts. Detection antibody produces a 
lower molecular weight nonspecific band in whole mouse tissue. Representative image of three 
independent experiments. (IP antibody: anti-p105/p50 (D7H5M CST), Detection antibodies: anti p50-
HRP [ab195854 Abcam] anti-HDAC1-HRP conjugate [ab193096 Abcam]. B. Predicted association of 
HDAC1 [Yellow & Blue, PDB ID: 4BKX] with a p50 homodimer [Orange, PDB ID: 1NFK] depicting two 
potential sites of interaction as solved by the GRAMM-X software for ridged body protein docking. C. 
Peptide array of 120 sequential peptides of 18 amino acids spanning the length of p50 probed with 
recombinant HDAC1-Hisx3 highlighting multiple sights of potential interaction (n=2 (anti-6x-His Tag 
Monoclonal Antibody HRP, R931-25, Invitrogen). D. All regions of potential interaction discovered in the 
peptide array mapped to the crystal structure of the p50 homodimer. 
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3.2 HDAC1 interacts with p50 at its nuclear localization signal. 
To better define the c-terminal binding site we employed scanning alanine substitutions into the 
peptides derived from this region that were previously shown to directly bind to recombinant 
HDAC1 and asked how these mutations affected the interaction. Fig 2A shows the resulting raw 
data which was used to locate an 7 amino acid long motif VQRKRQK (aa’s 359-365 of Human 
p50) which showed differential binding. Fig 2B illustrated the degree to which each residue 
contributes to this apparent loss of binding specifically in peptide 120. When mutated to alanine, 
residues in this motif reduce the ability of recombinant HDAC1 to bind with peptides as it had 
bound previously. On inspection we realized that the VQRKRQK motif lies within the p50 
nuclear localization signal (NLS) sequence at the far c-terminal of p50 and that this region is 
absent from the published protein crystal structure (Fig 2C).  To validate that this motif is 
required for HDAC1:p50 binding  in vivo we employed site-directed mutagenesis to generate a 
series of mutant c-terminal FLAG-tagged p50 cDNA expression constructs carrying one or more 
amino acid switches to alanine within the VQRKRQK region. WT and mutant p50-FLAG 
cDNAs together with an HA-tagged HDAC1 cDNA were co-transfected into Cos-7 cells to 
determine effects of combinations of VQRKRQK mutations on the interaction (Fig 2D). 
Intriguingly, sequential mutations of the V359, R361 and K362 residues up to R363 resulted in 
an apparent increase in HDAC1 interaction as determined by Co-IP, however a construct (p50Mu) 
that combines these sequential mutations with mutation of K365 resulted in an almost complete 
loss of HDAC1:p50 binding in the Co-IP (Fig 2D). Since independent mutation of K365 was 
insufficient to disrupt the HDAC1:p50 interaction (Supp. 2A), we conclude that multiple amino 
acid contacts are required for association with the VQRKRQK motif. Transfection of WT p50-
FLAG and p50Mu-FLAG constructs into human HeLa cells confirmed the ability of p50-FLAG 
to Co-IP endogenous HDAC1 and this experiment also validated in nfkb1-/- MEFs (Supp. 2B) 
that disruption of the VQRKRQK motif in p50Mu prevents the HDAC1 interaction (Fig 2E). 
Taken together these data provide evidence for sequence specificity of interaction of HDAC1 
with the c-terminal end of p50 and suggest that multiple amino acids within the previously 
identified NLS are required to form a p50:HDAC1 complex. The p50 NLS is proposed to have a 
helical-like structure but with a high degree of flexibility that may enable interaction with several 
distinct molecular targets such as members of the IκB family as well as the nuclear importin 
receptors [20]. 
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Figure 2. HDAC1 interaction is mediated by residues near the p50 nuclear localization sequence 
A. Alanine substitution peptide array of the terminal seven 18aa peptides probed with recombinant 
HDAC1 displaying differential binding based on specific amino acid changes (anti-6x-His Tag 
Monoclonal Antibody HRP, R931-25, Invitrogen). B. Representation listing all of the specific amino acids 
mutated to alanine within each peptide C. Residues which attenuate the interaction between HDAC1 and 
p50 peptides in context of the full-length protein D. Western blot analysis of a FLAG immunoprecipitation 
assay of indicated mutant p50 expressed in Cos7 cells transiently transfected along with HDAC1-HA. 
Complete mutation of the indicated residues (Sequence 4) result in a near total ablation of the 
p50:HDAC1 interaction in full length transiently transfected proteins (anti p50-HRP [ab195854 Abcam] 
anti-HDAC1-HRP conjugate [ab193096 Abcam]). E. Western blot analysis of a FLAG co-
immunoprecipitation assay of HELA cells transiently transfected with WT or p50Mu mutant confirming 
loss interaction with endogenous HDAC1 under resting conditions. Representative image of three 
independent experiments. Antibodies are those used in panel D. 
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3.3 Fundamental functions of p50 are unaffected by loss of the HDAC1 
interaction motif.  
We were next interested in determining the functional impacts of p50 mutations that perturb 
HDAC1 binding. As shown in Fig 3A, binding of p65 and IκBɑ was unaffected by mutations in 
the p50Mu protein in U20S cells. Similarly there was no effect of mutation of the VQRKRQK 
motif on the IκBα interaction in nfkb1-/- murine embryonic fibroblasts (Fig 3B), although we 
cannot rule out that pull down of IκBα occurred due to interaction with p65 in a p50Mu:p65:IκBα 
complex. We also observed no differences in the ability of WT p50 and p50Mu proteins to 
stimulate NF-κB-dependent transcription from co-transfected synthetic (3X κB-Luc) and natural 
(IκBα-Luc) promoters (Fig 3C). Hence, p50Mu retains the ability to assemble p65:p50 
heterodimers and to support classical canonical NF-κB signaling under the regulation of IκBα. 
Perhaps more unexpected was the lack of effect of the VQRKRQK mutations on nuclear 
expression of p50Mu, verified by Western blotting in nfkb1-/- MEFs and U20S cells (Fig 3D and 
Supp. 3A and B) and immunofluorescent localization (Fig 3E and Supp. 3C). Moreover, this 
nuclear localization occurs in both resting and TNFɑ stimulated MEF’s independent of expressed 
protein concentration (Supp. 2C). Additionally, ChIP assays on exogenously expressed FLAG-
tagged proteins suggested that VQRKRQK mutations displayed slight but non-significant 
reduction of binding of p50 with well-known target promoters cxcl1 and cxcl2, again confirming 
the presence of p50Mu in the nucleus of transformed cells (Fig 3F). These data therefore argue 
against an essential role of the NLS for p50 nuclear translocation and while being inconsistent 
with the original report that suggested an absolute requirement of the NLS, these data are in 
agreement with more recent published studies that experimentally demonstrate the NLS is 
probably non-essential for nuclear localization [10,21]. However, we did note that our 
immunofluorescence images suggested higher cytoplasmic expression for p50Mu compared with 
WT (Figure 3E). This observation may indicate that the NLS influences the efficiency of 
nuclear translocation. A caveat to this suggestion is an apparent technical difference between the 
Western blotting and immunofluorescence for detection of cytoplasmic p50, with the former we 
were able to detect similar abundant levels of cytoplasmic WT and mutant p50 proteins while 
with the latter we failed to observe WT p50 in the cytoplasm. Since our controls for nuclear 
contamination of cytoplasmic protein extracts were clean we are confident that the Western blot 
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is detecting cytoplasmic p50. A possible explanation for the differences between the protocols is 
that in the native state of the immunofluorescence experiments, the FLAG epitope may be 
somehow masked in the cytoplasm. Further, since the FLAG tag is fused to the c-terminal end of 
p50, mutations in this region in the p50Mu protein may have unmasked the FLAG epitope and 
explain why the mutant and not WT is detected. Despite these technical caveats, collectively the 
data show that the mutations in the NLS aimed at disruption of HDAC1 binding do not have a 
major impact on fundamental functions of p50 including its nuclear translocation or its ability to 
interact with target κB DNA binding sites. 
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Figure 3. Canonical interactions of p50 are unaffected by the HDAC1 interruption mutation 
A. FLAG immunoprecipitation of transiently expressed p50 in U2OS cells confirming similar co-
precipitation of the endogenous partner p65 and IκBɑ. B. Western blot co-immunoprecipitation of 
transfected p50 and endogenous p65 with endogenous IκBα pulldown confirming integrity of the 
canonical cytoplasmic inhibitory complex is unaffected by the p50Mu mutant in nfkb1-/- MEFs. C. 
Luciferase reporter assay for a 3x NF-κB promotor and IκBα promotor in nfkb1-/- MEFs reconstituted 
with WT or p50Mu confirming similar ability to promote NF-κB dependent gene transcription.                
D. Western blot of nuclear and cytoplasmic extracts from WT and transiently transfected nfkb1-/- MEFs 
(200ng/ml) showing p50 nuclear translocation is unaffected by the mutation despite its proximity to and 
inclusion of a portion of the nuclear localization sequence E. Immunofluorescence confocal microscopy 
of U2OS cells transiently transfected with WT-FLAG or p50Mu-FLAG detected by anti-FLAG-FITC 
confirming nuclear localization. (x400 Scale Bar =50μm). (anti-Flag-FITCI [F4049, Sigma]) F. ChIP 
assay for p50 in nfkb1-/- MEFs confirming similar binding at Cxcl1 and Cxcl2 promotors. All western 
blots are representative images of three independent experiments: anti-p105/p50-HRP (ab195854 
Abcam), anti-HDAC1-HRP (ab193096 Abcam), anti-p65 (sc372 Santa Cruz), anti-GAPDH (ab22555 
Abcam).  
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3.4 HDAC1:p50 regulates chromatin remodeling at neutrophil chemokine 
genes.  
Having established that disruption of the HDAC1 interaction motif did not affect p50 binding to 
κB sites in the Cxcl1 and Cxcl2 genes we next determined if there was an effect on local 
chromatin structure in the promoter regions of these genes. To this end, we performed ChIP 
assays using a pan-acetylated lysine Histone 3 (Ac-H3) antibody on chromatin isolated from 
nfkb1-/- MEFs expressing either WT p50-FLAG or p50Mu-FLAG proteins (Supp. 4A). As shown 
in Fig 4A, histone lysine acetylation density was enriched at the cxcl1 and cxcl2 promoters of 
cells expressing p50Mu relative to cells expressing the WT protein. This effect reached statistical 
significance for cxcl2, whereas a trend for enriched Ac-H3 was observed for Cxcl1. Hence, 
mutations in the p50 NLS that disrupt its interaction with HDAC1 results in a more 
transcriptionally active state of chromatin at promoters of genes encoding two key neutrophil 
chemokines. From these data we predicted that the expression of Cxcl1 and Cxcl2 and that of 
other known p50-target genes would be enhanced in cells expressing p50Mu. nfkb1-/- MEFs were 
therefore transfected with WT p50 or p50Mu (Fig 4B) prior to stimulation with TNFα and 
quantification of chemokine and cytokine gene expression. Quantification of mRNAs for Cxcl1 
and Cxcl2 revealed that TNFα stimulation was higher for both transcripts in the presence of 
p50Mu (Fig 4C). In addition, following TNFα stimulation transcripts for Il-6, Cxcl10 and Mmp13 
were also increased to a greater degree in the p50Mu transfected MEFs (Fig 4C). Moreover, 
ELISA for IL-6 in culture media confirmed that p50Mu transfected cells secreted higher levels of 
the cytokine in comparison to the WT transfectants (Fig 4D). Cells used in these experiments 
displayed a transfection efficacy of 73.7% (Supp. 4B). Finally, neutrophil migration assays 
revealed that conditioned media from TNF-stimulated p50Mu expressing cells (Supp. 4C) 
resulted in enhanced neutrophil chemotaxis compared with media from cells expressing WT p50 
(Fig 5). We conclude that the p50-HDAC1 interaction restricts neutrophil chemoattraction under 
conditions of inflammatory stimulation. 
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Figure 4. Loss of the p50:HDAC1 interaction leads to an increased pro-inflammatory profile 
A. Pan acetyl Histone 3 ChIP assay qRT-PCR demonstrating a significant increase in acetylation of the 
well-known p50 target gene Cxcl2 when nfkb1-/- MEFs are transfected with mutant p50 unable to bind 
HDAC1 (p50Mu) compared to WT (p=0.021). The same trend is observed in the target gene Cxcl1. B. 
Western blot analysis confirming equal transient transfection of WT and p50Mu in nfkb1-/- MEFs 
untreated or treated with TNFα (n=3) antibodies: anti-p50-HRP (ab195854 Abcam), anti-GAPDH 
(ab22555 Abcam). C. RT-qPCR demonstrating a significant increase in mRNA expression of well-known 
p50 repressed genes in the absence of HDAC1 interaction (p50Mu) in nfkb1-/- MEFs. Il-6 p=0.002, Cxcl2 
p=0.0002, Cxcl1 p=0.004, Cxcl10 p= 0.048 and Mmp13 p=0.0004 (n=3). D. ELISA analysis of cell 
media showing a significant increase in released IL-6 in nfkb1-/- MEFs stimulated with TNFα or 
unstimulated (p= 0.047) (n=3). 
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Figure 5. p50:HDAC1 represses neutrophil chemotaxis 
Schematic of a neutrophil chemotaxis highlighting timeframes and cell counts post chemotaxis of murine 
neutrophils showing increased chemotaxis toward p50Mu conditioned media and significantly more 
infiltration when nfkb1-/- MEFs reconstituted with WT or p50Mu are stimulated with TNFα post 
transfection (p = 0.046) (n=3). 
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4. Conclusion 
In summary, we present combined in silico, in vitro and in vivo data that supports a hypothesis 
that direct interaction of HDAC1 with p50 homodimers bound at κB sites of promoters and 
enhancers constitutes a key mechanism constricting NF-κB-dependent transcription of at least a 
subset of inflammatory genes. The NLS is now emerging as an important nexus for interaction of 
p50 with a number of different regulatory proteins; HDAC1 now joining Bcl3 and IκBα as 
identified NLS interacting factors. It is yet to be determined if these interactions are mutually 
exclusive. Bcl3 and HDAC1 seem to share at least the VQRKRQK motif which is required for 
each factor to complex with p50 but whether or not these are exclusive binding events warrants 
further investigation. As Bcl3 and HDAC1 provide distinct mechanisms through which p50 
negatively controls gene expression, they may provide context-specific regulation that is 
determined by cell type, distinct κB promoter/enhancer sequences, the nature of inflammatory 
signaling, influences of adjacent transcription factors or of other cofactors required for assembly 
of Bcl3 and HDAC1 repression complexes. As we observed an enrichment of lysine acetylation 
at Cxcl1 and Cxcl2 promoters when they were associated with p50Mu we suggest that this reflects 
disruption of an HDAC-mediated rather than Bcl3-regulated activity. As such, we propose that 
the controlled assembly of HDAC:p50:p50 complexes at neutrophil chemokine genes is a 
physiological requirement for effective control of neutrophilic inflammation.  
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Tables 
Mutagenesis Primers Tm 
AQAAAQA Forward agctcaggcgCTCATGCCCAATTTTTCG 60 
AQAAAQA Reverse gccgcctgcgcTTCTTCTTTATCTTTGATTTCAGG 60 
AQAAAQK Forward agctcagaagCTCATGCCCAATTTTTCG 60 
AQAAAQK Reverse gccgcctgcgcTTCTTCTTTATCTTTGATTTCAGG 60 
AQAARQK Forward acgtcagaagCTCATGCCCAATTTTTCG 60 
AQAARQK Reverse gccgcctgcgcTTCTTCTTTATCTTTGATTTCAGG 60 
VQAARQK Forward acgtcagaagCTCATGCCCAATTTTTCG 60 
VQAARQK Reverse gccgcctgcacTTCTTCTTTATCTTTGATTTCAGG 60 
VQRARQK Forward acgtcagaagCTCATGCCCAATTTTTCG 60 
VQRARQK Reverse gccctctgcacTTCTTCTTTATCTTTGATTTCAGG 60 
qRT-PCR Primers 
mIL-6 Forward GAGGATACCACTCCCAACAGA 60 
mIL-6 Reverse AAGTGCATCATCGTTGTTCATA 60 
mCXCL1 Forward CTGGGATTCACCTCAAGAACATC 60 
mCXCL1 Reverse CAGGGTCAAGGCAAGCCTC 60 
mCXCL2 Forward CCAACCACCAGGCTACAGG 60 
mCXCL2 Reverse GCGTCACACTCAAGCTCTG 60 
mCXCL10 Forward AAGTGCTGCCGTCATTTCT 57 
mCXCL10 Reverse GTGGCAATGATCTCAACACG 57 
mMMP13 Forward CTTCTTCTTGTTGAGCTGGACTC 57 
mMMP13 Reverse CTGTGGAGGTCACTGTAGACT 57 
ChIP Primers 
mCXCL1 Forward GTTGGCAAAAGCAAACCACC 57 
mCXCL1 Reverse ACTACAGTGATTTGCGGGGA 57 
mCXCL2 Forward GACATCCCAGGGTCCCATAG 57 
mCXCL2 Reverse TGCACGATGTCTGGAAAAGC 57 
 
Table 1 
Table of primers used for site directed mutagenesis, RT-qPCR and Chromatin 
immunoprecipitation PCR. 
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   Concentration 
Construct Backbone IP/Functional Luciferase Assay 
WT-p50-FLAG pcDNA3.1 200ng/ml 250ng/ml 
VQRARQK- p50-FLAG pcDNA3.1 200ng/ml 250ng/ml 
AQAARQK-p50-FLAG pcDNA3.1 200ng/ml 250ng/ml 
AQAAAQK-p50-FLAG pcDNA3.1 200ng/ml 250ng/ml 
AQAAAQA-p50-FLAG pcDNA3.1 200ng/ml 250ng/ml 
3x κB-Luc Reporter pGL-2 N/A 250ng/ml 
CTL-Luc Reporter pGL-2 N/A 250ng/ml 
IκBα-Luc Reporter pGL-2 N/A 250ng/ml 
Renilla- Luc-Reporter pGL-2 N/A 25ng/ml 
 
Table 2 
Table of DNA plasmid constructs and the amounts used in the indicated application. 
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Supplemental Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 1 
A. Endogenous co-immunoprecipitation western blot of HELA cells which were untreated or treated 
with TNFα showing a reduction of HDAC1 interaction when stimulated (anti-p50-HRP (ab195854 
Abcam), anti-HDAC1-HRP (ab193096 Abcam). B. Top ten highest scoring possible binding 
orientations between the p50 homodimer and HDAC1 crystal structures as predicted by the GRAMM-
X server for rigid body interactions. C. p50 peptide array under UV light verifying the presence of 
120 individual peptides spanning the length of p50. D. p50 peptide array probed with Anti-His3X-
HRP antibody alone showing a lack of non-specific binding derived from the antibody used. 
 
28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 2 
A. Western blot analysis of a FLAG Co-IP assay showing similar binding of HDAC1 to WT or 
p50K365A mutant in Cos7 cells. B. Western blot analysis of a FLAG Co-IP assay of nfkb1-/- MEFs 
showing a loss of interaction with endogenous HDAC1 in p50Mu Compared to WT. C. Western blot of 
nuclear and cytoplasmic extracts from WT and transiently transfected nfkb1-/- MEFs (50ng/ml of WT 
or p50Mu) showing p50 nuclear translocation is unaffected by the mutation required to disrupt 
HDAC1 interaction despite its proximity to and inclusion of a portion of the nuclear localization 
sequence at reduced transient expression levels. [Detection antibodies anti-p105/p50-HRP (ab195854 
Abcam), anti-HDAC1-HRP (ab193096 Abcam), and, anti-GAPDH (ab22555 Abcam).  
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Supplemental Figure 3 
A. Western blot of nuclear and cytoplasmic extracts from transiently transfected U2OS cells showing 
p50 nuclear translocation is unaffected by the mutation required to disrupt HDAC1 interaction 
despite its proximity to and inclusion of a portion of the nuclear localization sequence [anti-p50-HRP 
(ab195854 Abcam), anti-HDAC1-HRP (ab193096 Abcam)] and anti-GAPDH (ab22555 Abcam).          
B. Western blot of nuclear and cytoplasmic extracts from transiently transfected nfkb1-/- MEFs 
(200ng/ml) showing p50 nuclear translocation is unaffected by the mutation required to disrupt 
HDAC1 interaction despite its proximity to and inclusion of a portion of the nuclear localization 
sequence C. Immunofluorescence confocal microscopy of U2OS cells transiently transfected with WT-
FLAG or p50Mu-FLAG detected by anti-FLAG-FITC confirming nuclear localization. (x200 Scale 
Bar =50μm). (anti-Flag-FITCI [F4049, Sigma]).  
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Supplemental Figure 4 
A. Western blot showing comparable transfection of WT and p50Mu from nfkb1-/- MEFs whose 
chromatin was used in pan H3 acetylation ChIP experiments. B. Transfection efficiency of nfkb1-/- 
MEFs transfected with 200ng/ml GFP reporter vector (73.7% x100 Scale Bar=50um)). C. Western 
blot showing comparable transfection of WT and p50Mu from nfkb1-/- MEFs whose supernatant was 
used in the neutrophil chemotaxis experiments in both the presence and absence of TNFα. 
